About 10% of employers who now cover GLP-1 drugs for weight loss plan to drop the drugs in 2027, according to the Business Group on Health.[1010439] GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology.[956045] In other news, AstraZeneca is developing an obesity pill that shows promise in early trials.[1010439] The Business Group on Health says 44% of companies with more than 500 employees cover the drugs for obesity.[1010439]